Loading stock data…
Tarsus Pharmaceuticals, Inc. (TARS)
$58.66+0.08 (+0.14%)
Market ClosedLast close Jul 24
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $58.66 with a market capitalization of $2.5B. Wall Street consensus targets $94.44 (9 analysts), implying a +61.0% move over the next 12 months. The stock is currently 31% below its 52-week high of $85.25, remaining 14.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +61.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $162.05M↑ | $151.67M↑ | $118.70M↑ | $102.66M↑ | $78.33M |
| Gross Profit | $152.66M↑ | $140.74M↑ | $110.39M↑ | $96.42M↑ | $73.12M |
| Operating Income | -$6.12M↑ | -$7.98M↑ | -$14.53M↑ | -$22.18M↑ | -$26.28M |
| Net Income | -$6.97M↑ | -$8.37M↑ | -$12.59M↑ | -$20.34M↑ | -$25.12M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.53B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.83%
Volume
Today's trading volume
446,493
Recent News
Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue
Tarsus Pharmaceuticals (NasdaqGS:TARS) announced the departure of its Chief Commercial Officer. The company appointed an interim commercial leader to oversee ongoing operations. Tarsus is engaged in M&A discussions with iRenix Medical. Tarsus Pharmaceuticals focuses on treatments in ophthalmology and related areas, which puts execution around commercial plans at the center of the story for many investors. A change in the Chief Commercial Officer role, combined with an interim appointment,...
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market. On an investor call discussin
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.